Sygnature Discovery is a leading independent provider of integrated drug discovery and pre-clinical resource and expertise. We undertake target validation, hit identification, hit-to-lead and lead optimisation projects and complete drug discovery programs. We offer fully integrated discovery project support, as well as discipline specific support in chemistry, computational sciences, in vitro biology, ADME or in vivo pharmacology as needed by our collaborating clients.
Sygnature adds significant value to collaborations by providing advanced scientific knowledge and intellectual input to accelerate clients’ drug discovery projects from target validation and lead optimisation through to pre-clinical candidate. Since 2011, 31 compounds discovered by Sygnature for clients have entered pre-clinical development and so far, 15 of these have progressed to clinical trials (Phases I, II and III).
A multi award-winning company, Sygnature operates fully enabled research facilities in Nottingham and Alderley Park, UK, housing the most technologically advanced laboratories and teams of expert scientists (>80% with PhDs).
Wednesday, 18th November, 2020
10:00am GMT (UTC+0)
hosted by Lilly Xu, Ph.D. Senior Vice President, DMPK & Exploratory Toxicology Dept, ChemPartner